Hexarelin

Hexarelin (Examorelin) – Growth Hormone Secretagogue Research Peptide

Synthetic Hexapeptide for Ghrelin Receptor Signaling, Growth Hormone Secretion, Cardiovascular Physiology & Neuroendocrine Research

Hexarelin, also known as Examorelin, is a synthetic hexapeptide belonging to the family of growth hormone secretagogues (GHS). It has been investigated for its ability to stimulate endogenous growth hormone (GH) secretion through activation of the growth hormone secretagogue receptor type 1a (GHS-R1a).

Hexarelin was developed through research on synthetic growth hormone-releasing peptides and has been examined in both preclinical models and controlled human endocrine studies.

Like GHRP-2 and GHRP-6, Hexarelin activates signaling pathways associated with the ghrelin receptor. However, it possesses a distinct molecular structure and has attracted additional scientific interest because of findings involving cardiac physiology and cardiovascular signaling.

Experimental studies have demonstrated acute growth hormone-releasing activity. Researchers have also examined Hexarelin-associated effects on prolactin, ACTH, cortisol and cardiac function.

Importantly, evidence of endocrine or cardiovascular activity does not establish Hexarelin as a safe or effective treatment for muscle growth, fat loss, heart disease, recovery or aging.

ICAME Pharmacy Hexarelin is intended strictly for laboratory research and development purposes. Not for human or veterinary use.

What Is Hexarelin?

Hexarelin is a synthetic peptide consisting of six amino acid residues, including modified amino acids that contribute to its pharmacological characteristics.

It belongs to the growth hormone secretagogue family, which includes several synthetic peptides developed to investigate GH secretion.

Hexarelin is structurally related to GHRP-6 but contains modifications that influence its receptor interactions and biological activity.

The compound has been investigated in research involving:

• Growth hormone secretion

• Ghrelin receptor pharmacology

• Hypothalamic–pituitary signaling

• GH–IGF-1 axis physiology

• Pituitary hormone regulation

• ACTH and cortisol responses

• Prolactin-associated signaling

• Cardiac function

• Cardiomyocyte biology

• Cardiovascular receptor interactions

• Receptor desensitization

• Peptide structure–activity relationships

Hexarelin is not recombinant human growth hormone.

It acts as a growth hormone secretagogue, meaning it stimulates endogenous GH-releasing pathways under appropriate experimental conditions.

Hexarelin Molecular Structure

Hexarelin is a synthetic hexapeptide containing six amino acid residues.

Amino Acid Sequence

H-His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH₂

The sequence contains:

His — Histidine

D-2-Me-Trp — D-2-Methyltryptophan

Ala — Alanine

Trp — Tryptophan

D-Phe — D-Phenylalanine

Lys — Lysine

The peptide has an amidated C-terminus.

Molecular Characteristics

Compound Name: Hexarelin

Alternative Name: Examorelin

Peptide Classification: Synthetic Growth Hormone Secretagogue

Peptide Length: 6 Amino Acid Residues

Molecular Formula: C₄₇H₅₈N₁₂O₆

Approximate Molecular Weight: 887.0 g/mol

CAS Number: 140703-51-1

Primary Receptor: GHS-R1a

Additional Research-Associated Binding Partner: CD36

Principal Research Fields: Endocrinology / Receptor Pharmacology / Cardiovascular Biology

These specifications describe the commonly referenced parent Hexarelin molecule.

Commercial preparations may contain counterions, salts or other formulation-related components. Product-specific molecular identity and analytical specifications should therefore be confirmed through a Certificate of Analysis.

Discovery and Scientific Background

Growth hormone-releasing peptides were developed to investigate mechanisms of GH secretion beyond the classical growth hormone-releasing hormone pathway.

Early studies identified synthetic peptides capable of stimulating pituitary GH release.

GHRP-6 became an important reference compound in this research field.

Hexarelin was subsequently developed as a structurally modified member of the GHRP family.

Its ability to stimulate GH secretion was investigated in experimental animals and humans.

Research later identified the growth hormone secretagogue receptor, helping explain the endocrine activity of these compounds.

The discovery of ghrelin in 1999 as an endogenous GHS-R1a ligand further expanded understanding of the receptor's physiological functions.

Hexarelin also became an important compound in cardiovascular research when investigators reported biological effects that could not be explained solely by GH secretion.

These findings contributed to research into alternative binding partners, including CD36.

How Does Hexarelin Work?

Hexarelin acts primarily as an agonist of GHS-R1a, a G protein-coupled receptor involved in GH secretion and neuroendocrine regulation.

Receptor activation initiates intracellular signaling associated with pituitary hormone release.

Simplified Mechanism of Action

Hexarelin

↓

GHS-R1a Receptor Activation

↓

Gq/11-Associated Signaling

↓

Phospholipase C (PLC) Activation

↓

IP₃ / DAG Signaling

↓

Intracellular Calcium Mobilization

↓

Stimulation of Pituitary GH Secretion

↓

Investigation of GH–IGF-1 Axis Responses

This pathway represents an established aspect of growth hormone secretagogue receptor signaling.

However, Hexarelin has also been investigated for effects involving other molecular interactions, particularly in cardiovascular research.

Its biological profile should therefore not be reduced to GH secretion alone.

Hexarelin and the Ghrelin Receptor (GHS-R1a)

The growth hormone secretagogue receptor type 1a is the principal signaling receptor associated with the endogenous hormone ghrelin.

Ghrelin participates in several physiological processes, including:

Growth hormone secretion

Appetite-associated signaling

Energy balance

Hypothalamic regulation

Neuroendocrine physiology

Hexarelin activates GHS-R1a despite having a different molecular structure from ghrelin.

This makes it relevant to research involving:

• Receptor activation

• Ligand–receptor recognition

• G protein-coupled receptor signaling

• Intracellular calcium responses

• Pituitary GH release

• Synthetic peptide pharmacology

However, the physiological effects of Hexarelin should not automatically be assumed to match those of endogenous ghrelin.

Hexarelin and Growth Hormone Secretion

Growth hormone is produced by somatotroph cells in the anterior pituitary gland.

GH secretion is regulated by several interacting systems.

Important regulators include:

Growth Hormone-Releasing Hormone (GHRH)

Somatostatin

Ghrelin

Metabolic Signals

Sleep-Associated Physiology

GH and IGF-1 Feedback

Hexarelin has been shown to stimulate acute GH secretion in human endocrine studies.

Its activity has been investigated in healthy volunteers and selected patient populations.

These findings establish Hexarelin as a biologically active GH secretagogue.

However, an acute increase in circulating GH does not demonstrate sustained improvements in body composition, muscle strength or physical performance.

Hexarelin and the GH–IGF-1 Axis

The growth hormone–insulin-like growth factor-1 (GH–IGF-1) axis is involved in growth, metabolism and tissue physiology.

GH is released by the anterior pituitary.

It acts on target tissues, including the liver, where it can stimulate IGF-1 production.

GH–IGF-1 Signaling Overview

Hypothalamic Regulation

↓

Pituitary GH Secretion

↓

GH Receptor Activation

↓

IGF-1-Associated Signaling

↓

Growth and Metabolic Regulation

Hexarelin acts upstream by stimulating GH secretion.

It is not equivalent to administering GH or IGF-1 directly.

Furthermore, the relationship between acute GH stimulation and longer-term IGF-1 changes depends on physiological conditions and the pattern of exposure.

Hexarelin and Hypothalamic–Pituitary Research

The hypothalamus and pituitary gland coordinate several endocrine functions.

Hexarelin has been investigated as a tool for studying pituitary responsiveness and hypothalamic regulation.

Relevant research areas include:

Somatotroph function

GH pulsatility

Pituitary hormone release

Hypothalamic feedback

Receptor-mediated secretion

Neuroendocrine interactions

Hexarelin's activity differs from that of GHRH because it activates a different receptor system.

This distinction has made it useful in comparative endocrine research.

Hexarelin and GHRH: Different Signaling Systems

Growth hormone-releasing hormone (GHRH) is an endogenous hypothalamic hormone that stimulates GH secretion.

It acts through the GHRH receptor.

Hexarelin activates GHS-R1a.

Experimental studies have examined interactions between the GHS-R1a and GHRH receptor pathways.

These findings contribute to understanding GH secretion but do not establish the safety or efficacy of combining research compounds.

Hexarelin and Cardiovascular Research

One of the distinctive aspects of Hexarelin is its history in cardiovascular research.

Investigators have examined Hexarelin-associated effects on:

• Cardiac contractility

• Myocardial function

• Ischemia-associated injury

• Cardiomyocyte responses

• Cardiovascular signaling

• Cardiac remodeling

• Receptor interactions in heart tissue

Some preclinical studies reported potentially protective effects in experimental models of cardiac injury.

Small human physiological studies have also examined acute cardiovascular responses.

However, these findings do not establish Hexarelin as an effective treatment for heart failure, ischemic heart disease or other cardiovascular conditions.

The cardiovascular evidence remains limited and highly dependent on the experimental model.

Hexarelin and CD36 Receptor Research

CD36 is a multifunctional membrane protein involved in several biological processes.

These include lipid transport, fatty acid metabolism and cellular signaling.

Research has identified CD36 as a binding partner associated with Hexarelin and certain synthetic growth hormone secretagogues.

This finding is particularly important because it provides a possible explanation for some biological effects that may occur independently of classical pituitary GH secretion.

Simplified Research Framework

Hexarelin

↓

GHS-R1a-Associated Endocrine Signaling

and

CD36-Associated Experimental Interactions

↓

Investigation of Cardiovascular and Metabolic Responses

The exact contribution of each pathway varies by experimental system.

CD36-associated binding should not be interpreted as proof of a fully established therapeutic mechanism in humans.

Hexarelin and Cardiomyocyte Biology

Cardiomyocytes are specialized muscle cells responsible for the contractile activity of the heart.

Their function depends on coordinated calcium signaling, energy metabolism and cellular structural integrity.

Hexarelin has been investigated in experimental models examining cardiomyocyte-associated responses.

Research topics include:

Cardiac cellular signaling

Contractile function

Cellular stress responses

Metabolic regulation

Myocardial injury models

Receptor-mediated activity

Some preclinical studies have reported changes in cellular responses associated with cardiac injury.

However, these findings do not establish clinically meaningful myocardial protection in humans.

Hexarelin and Ischemia–Reperfusion Research

Ischemia–reperfusion injury occurs when blood flow is restored after a period of reduced oxygen supply.

This process can involve oxidative stress, inflammation and cellular injury.

Experimental studies have investigated Hexarelin in models of ischemia-associated myocardial damage.

Reported research endpoints include:

Cardiac function

Cellular injury markers

Oxidative stress-associated responses

Myocardial remodeling

Contractility

These studies have contributed to interest in the cardiovascular pharmacology of Hexarelin.

However, the results are predominantly preclinical.

They should not be interpreted as evidence that Hexarelin prevents heart attacks or treats cardiovascular disease.

Hexarelin and Cardiac Contractility

Cardiac contractility refers to the ability of the heart muscle to generate force.

It is influenced by intracellular calcium handling, myocardial structure and neurohormonal regulation.

Hexarelin has been investigated in experimental studies involving cardiac contractile responses.

Some early human studies examined acute changes in cardiac function following exposure to growth hormone secretagogues.

These observations generated interest in possible GH-independent cardiovascular mechanisms.

However, short-term physiological changes do not establish long-term clinical benefit.

Hexarelin is not an established treatment for reduced cardiac contractility.

Hexarelin and Prolactin Research

Prolactin is a pituitary hormone involved in reproductive and metabolic physiology.

Growth hormone secretagogues can influence more than one pituitary hormone pathway.

Human studies involving Hexarelin have reported prolactin-associated endocrine responses.

These findings make the compound relevant to research involving:

Pituitary hormone selectivity

Lactotroph signaling

Neuroendocrine regulation

Hormonal feedback

Receptor-mediated secretion

Hexarelin should therefore not be characterized as completely selective for GH secretion.

Hexarelin and ACTH Research

Adrenocorticotropic hormone (ACTH) is secreted by the anterior pituitary gland.

It stimulates cortisol production by the adrenal cortex.

Hexarelin has been investigated in human endocrine studies examining ACTH-associated responses.

HPA Axis Overview

Hypothalamus

↓

Pituitary ACTH Release

↓

Adrenal Cortex

↓

Cortisol Secretion

Experimental results indicate that Hexarelin can influence HPA-axis hormone secretion under certain conditions.

This broader endocrine activity is important when interpreting its biological profile.

Hexarelin and Cortisol Research

Cortisol is a glucocorticoid hormone involved in metabolic regulation and physiological stress responses.

Human endocrine studies have reported cortisol responses following Hexarelin exposure.

The magnitude of these responses may vary according to physiological conditions and study design.

Relevant research areas include:

HPA-axis physiology

Pituitary hormone interactions

Stress-associated endocrine signaling

Glucocorticoid regulation

Hormonal feedback

Increased cortisol secretion is not necessarily beneficial.

The possibility of additional endocrine responses is an important consideration when evaluating the selectivity of Hexarelin.

Hexarelin and Receptor Desensitization

Receptor desensitization refers to a reduction in cellular responsiveness following repeated or prolonged stimulation.

Growth hormone secretagogue research has examined changes in GH responses after repeated exposure.

Hexarelin has been investigated in studies involving:

Repeated receptor activation

GH response attenuation

Pituitary responsiveness

Endocrine feedback

Receptor regulation

Some research has reported reduced GH responses following repeated stimulation.

However, the degree of attenuation depends on the experimental setting.

This phenomenon is relevant to understanding receptor regulation and does not provide a basis for unsupervised administration strategies.

Hexarelin and Appetite Regulation

The ghrelin receptor participates in appetite-associated signaling.

Because Hexarelin activates GHS-R1a, it has been investigated in relation to metabolic and feeding pathways.

Relevant research topics include:

Ghrelin receptor signaling

Hypothalamic feeding circuits

Energy balance

Nutritional regulation

Neuroendocrine metabolism

However, Hexarelin's appetite-related effects should not automatically be assumed to match those of GHRP-6 or endogenous ghrelin.

Differences in ligand structure, tissue responses and experimental conditions may influence the observed outcomes.

Hexarelin is not an established treatment for appetite disorders.

Hexarelin and Metabolic Research

Growth hormone and ghrelin receptor signaling participate in several metabolic processes.

These include:

Glucose metabolism

Lipid metabolism

Energy balance

Nutrient-related signaling

Endocrine feedback

Hexarelin has been investigated in experimental metabolic research.

Its interactions with GHS-R1a and CD36 have generated interest in different aspects of cellular metabolism.

However, the evidence does not establish Hexarelin as an effective treatment for obesity, diabetes or metabolic disorders.

Changes in GH signaling may also influence glucose regulation and insulin sensitivity.

Hexarelin and Skeletal Muscle Research

Growth hormone and IGF-1 participate in biological pathways associated with growth and tissue metabolism.

Because Hexarelin stimulates endogenous GH secretion, it has been discussed in relation to skeletal muscle research.

Relevant research topics include:

GH receptor biology

IGF-1-associated signaling

Muscle protein regulation

Growth-associated pathways

Endocrine responses

Tissue metabolism

However, there is insufficient high-quality clinical evidence to establish that Hexarelin increases muscle mass or strength in healthy humans.

An acute GH response does not demonstrate muscle hypertrophy.

Hexarelin and Body Composition Research

Body composition depends on multiple physiological and behavioral factors.

These include:

Energy intake

Physical activity

Hormonal regulation

Muscle metabolism

Adipose tissue biology

Age and genetics

Hexarelin has been discussed in body composition research because of its effects on GH secretion.

However, clinical evidence does not establish reliable fat loss, muscle gain or body recomposition.

The compound should not be marketed as a proven weight-management or bodybuilding treatment.

Hexarelin and Aging-Related Endocrine Physiology

Growth hormone secretion changes with age.

These changes have been investigated in relation to metabolism, sleep and body composition.

Hexarelin has been studied in endocrine research involving age-associated differences in pituitary responsiveness.

Research areas include:

Age-related GH secretion

Pituitary function

Endocrine feedback

Hormonal rhythms

Metabolic physiology

However, increasing GH secretion is not equivalent to reversing biological aging.

Hexarelin has not been established as a safe or effective longevity treatment.

Hexarelin and Sleep-Associated GH Physiology

GH secretion is associated with sleep physiology.

A prominent GH secretory pulse often occurs during early nocturnal sleep.

Growth hormone secretagogues have been investigated in studies examining the relationship between endocrine signaling and sleep.

Hexarelin may be relevant to research involving:

GH pulsatility

Sleep-associated endocrine rhythms

Hypothalamic signaling

Pituitary responses

Neuroendocrine regulation

However, there is insufficient evidence to establish Hexarelin as an effective treatment for insomnia or sleep disorders.

Hexarelin and Peptide Structure–Activity Relationships

Structure–activity relationship (SAR) research examines how changes in molecular structure influence biological activity.

Hexarelin contains modified amino acid residues, including D-amino acids.

Its sequence differs from that of GHRP-6 through the presence of a methylated tryptophan residue.

These modifications are relevant to investigations involving:

Receptor affinity

Biological potency

Peptide stability

Receptor selectivity

Endocrine responses

Ligand–receptor recognition

Hexarelin provides a useful model for studying synthetic peptide design and growth hormone secretagogue pharmacology.

Hexarelin vs. GHRP-6

Hexarelin and GHRP-6 are structurally related synthetic hexapeptides.

Both activate GHS-R1a-associated signaling.

However, their amino acid sequences differ.

Differences in experimental potency or receptor interactions do not establish superior clinical outcomes.

Hexarelin vs. GHRP-2

Hexarelin and GHRP-2 belong to the growth hormone secretagogue family.

Both are synthetic hexapeptides.

Their structures and experimental pharmacological profiles differ.

Direct comparisons require consideration of study design, population and measured endpoints.

Neither compound should be marketed as a clinically validated muscle-building or anti-aging treatment.

Hexarelin vs. Ipamorelin

Hexarelin and ipamorelin are synthetic GH secretagogues.

Both have been investigated for their ability to stimulate GH secretion through GHS-R1a-associated pathways.

Ipamorelin was developed with an emphasis on selective GH-releasing activity in early experimental studies.

Hexarelin has a broader research history involving additional pituitary hormones and cardiovascular biology.

These differences are relevant to endocrine pharmacology.

However, neither compound has established clinical efficacy for muscle growth, fat loss or longevity in healthy humans.

Hexarelin vs. CJC-1295

Hexarelin and CJC-1295 act through different receptor systems.

Hexarelin activates GHS-R1a.

CJC-1295 is a modified GHRH analogue that activates the GHRH receptor.

The compounds should not be considered interchangeable.

Research involving different GH secretagogue pathways does not establish the safety of combining experimental peptides.

Human Research on Hexarelin

Hexarelin has been investigated in controlled human endocrine studies.

These studies provide evidence of acute biological activity.

Growth Hormone Secretion

Human studies have demonstrated that Hexarelin stimulates GH secretion.

Pituitary Hormone Responses

Research has reported additional endocrine responses involving prolactin, ACTH and cortisol.

Cardiovascular Physiology

Small human studies have investigated acute cardiovascular responses.

Repeated Exposure

Some investigations have examined changes in GH responsiveness following repeated stimulation.

Important Limitation

These studies do not establish Hexarelin as an approved general-purpose treatment for GH deficiency, cardiovascular disease, muscle growth, body composition or aging.

The clinical relevance of experimental findings depends on the specific formulation, study design and patient population.

Potential Safety Concerns

Hexarelin influences multiple endocrine and potentially cardiovascular pathways.

Important scientific considerations include:

Growth Hormone Regulation

Changes in GH secretion may affect metabolic and endocrine systems.

Prolactin Responses

Human studies have reported prolactin-associated effects.

ACTH and Cortisol

Hexarelin may stimulate HPA-axis hormone secretion.

Glucose Regulation

Changes in GH signaling may influence glucose metabolism.

Cardiovascular Responses

Experimental cardiovascular activity requires careful evaluation rather than assumptions of benefit.

Receptor Desensitization

Repeated stimulation may alter endocrine responsiveness.

Long-Term Safety

Long-term systemic safety has not been adequately established for unapproved Hexarelin preparations.

Product Quality

Research materials may differ in molecular identity, purity, salt form and analytical specifications.

No research-grade peptide should be assumed suitable for human administration.

Hexarelin and Anti-Doping Regulations

Hexarelin, also known as examorelin, is included among prohibited growth hormone secretagogues under the World Anti-Doping Agency (WADA) framework.

It is prohibited in sport both in and out of competition.

Its availability as a research compound does not exempt it from anti-doping restrictions.

Researchers and distributors should consult applicable national regulations governing peptide substances.

Scientific Evidence and Research Limitations

Hexarelin has a substantial history in experimental endocrine and cardiovascular pharmacology.

However, evidence quality varies considerably across proposed applications.

Established Research Findings

• Hexarelin is a synthetic hexapeptide.

• It activates GHS-R1a-associated signaling.

• It stimulates acute GH secretion in humans.

• Human studies have documented additional pituitary hormone responses.

• Experimental cardiovascular effects have been reported.

• CD36-associated binding has been investigated.

• Repeated stimulation can influence endocrine responsiveness.

Important Limitations

• Clinical efficacy for muscle growth is not established.

• Clinical efficacy for fat loss is not established.

• Cardiovascular therapeutic efficacy is unproven.

• Anti-aging and longevity claims are unsupported.

• Acute GH secretion does not guarantee sustained clinical benefit.

• Long-term systemic safety is insufficiently characterized.

• Research-grade products are not equivalent to authorized pharmaceuticals.

• Unsupervised human use may involve significant endocrine and product-quality risks.

These limitations should be clearly communicated in scientific product descriptions.

Potential Research Applications

Hexarelin may be relevant to appropriately controlled scientific investigations involving:

• Growth hormone secretion

• Ghrelin receptor pharmacology

• GHS-R1a activation

• Hypothalamic–pituitary physiology

• GH–IGF-1 axis research

• G protein-coupled receptor signaling

• Phospholipase C pathways

• Intracellular calcium signaling

• Pituitary somatotroph function

• Prolactin-associated responses

• ACTH and cortisol regulation

• Cardiovascular physiology

• Cardiomyocyte biology

• CD36 receptor research

• Myocardial injury models

• Cardiac contractility

• Receptor desensitization

• Metabolic signaling

• Peptide structure–activity relationships

• Synthetic peptide chemistry

These are scientific research areas rather than established therapeutic benefits.

Hexarelin Research Overview

Compound Name: Hexarelin

Alternative Name: Examorelin

Classification: Synthetic Growth Hormone Secretagogue

Peptide Length: 6 Amino Acid Residues

Sequence: H-His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH₂

Molecular Formula: C₄₇H₅₈N₁₂O₆

Approximate Molecular Weight: 887.0 g/mol

CAS Number: 140703-51-1

Primary Receptor: GHS-R1a

Additional Research-Associated Binding Partner: CD36

Principal Experimental Effect: Stimulation of GH Secretion

Additional Research Areas: Cardiovascular Biology / Prolactin / ACTH / Cortisol

Clinical Performance Benefits: Not established

Anti-Doping Status: Prohibited under WADA rules

Product Information

Product Name: Hexarelin

Alternative Name: Examorelin

Brand: ICAME Pharmacy

Product Category: Research Peptide

Research Classification: Synthetic Growth Hormone Secretagogue

Research Areas: GH Secretion / Ghrelin Receptor Signaling / Cardiovascular Physiology

Intended Use: Laboratory Research & Development Only

The exact identity and specifications of the supplied material should be confirmed through manufacturer documentation.

Relevant batch-specific information includes:

• Verified amino acid sequence

• Chemical form and counterion

• Molecular identity

• Analytical purity

• Peptide content

• Certificate of Analysis (COA)

• Batch/lot identification

• Validated storage conditions

No claims of pharmaceutical quality, sterility, human suitability or therapeutic efficacy should be made without appropriate supporting documentation and regulatory authorization.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, muscle-building, weight-loss, cardiovascular treatment, performance-enhancing, anti-aging or other clinical purposes. Not for direct administration to humans or animals.

Hexarelin is a biologically active growth hormone secretagogue.

Human studies demonstrate acute endocrine activity, including GH secretion and possible additional hormonal responses.

Experimental cardiovascular findings do not establish therapeutic efficacy or safety in humans.

Long-term systemic safety and clinical benefits for performance, body composition and aging-related outcomes have not been established.

Hexarelin is prohibited in sport under anti-doping regulations.

Information presented on this page is intended solely for scientific and educational purposes and does not constitute medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to peptide science, endocrinology, molecular biology, receptor signaling, experimental pharmacology and life sciences research.

We emphasize accurate product identification, responsible research use, scientific transparency and clear communication of evidence limitations.

For batch-specific analytical documentation and product inquiries, please contact ICAME Pharmacy.

Frequently Asked Questions About Hexarelin

What is Hexarelin?

Hexarelin is a synthetic hexapeptide growth hormone secretagogue investigated for its ability to stimulate GH secretion through GHS-R1a-associated pathways.

Is Hexarelin the same as Examorelin?

Yes. Examorelin is an alternative name for Hexarelin.

What receptor does Hexarelin activate?

Its principal endocrine target is the ghrelin receptor, GHS-R1a. CD36-associated interactions have also been investigated in cardiovascular research.

Does Hexarelin stimulate growth hormone secretion?

Yes. Controlled human studies have demonstrated acute GH secretion following Hexarelin exposure.

Is Hexarelin the same as GHRP-6?

No. Hexarelin and GHRP-6 are structurally related but distinct synthetic hexapeptides.

Is Hexarelin a cardiovascular treatment?

No. Although experimental cardiovascular effects have been reported, Hexarelin has not been established as an effective treatment for cardiovascular disease.

Does Hexarelin increase muscle mass?

Clinical evidence is insufficient to establish meaningful muscle growth or strength improvements in healthy humans.

Does Hexarelin increase cortisol?

Some human endocrine studies have reported cortisol-associated responses following Hexarelin exposure.

Is Hexarelin prohibited in sport?

Yes. Hexarelin is included among prohibited growth hormone secretagogues under WADA regulations.

Is ICAME Pharmacy Hexarelin intended for human use?

No. ICAME Pharmacy Hexarelin is intended strictly for laboratory research and development purposes.